Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: An immunohistochemical study

Gynecologic Oncology

Volumn 103, Issue 1, 2006, Pages 186-189

  Bodner Adler, Barbara ^a   Nather, Andreas ^a   Bodner, Klaus ^a   Czerwenka, Klaus ^a   Kimberger, Oliver ^a   Leodolter, Sepp ^a   Mayerhofer, Klaus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinicopathologic parameters; Leiomyoma; Thrombospondin 1 expression; Uterine leiomyosarcoma; Uterine smooth muscle tumor of uncertain malignant potential

Indexed keywords

THROMBOSPONDIN 1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MUSCLE TUMOR; PRIORITY JOURNAL; TUMOR DIAGNOSIS; TUMOR RECURRENCE; UTERUS TUMOR;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; SMOOTH MUSCLE TUMOR; THROMBOSPONDIN 1; UTERINE NEOPLASMS;

EID: 33748700264     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.02.023     Document Type: Article

References (24)

1. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3 (1992) 65-71
2. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
3. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 79 (1997) 1-8
4. Weinstat-Saslow D.L., Zabrenetzky V.S., VanHoutte K., Frazier W.A., Roberts D.D., and Steeg P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54 (1994) 6504-6511
5. Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L., et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinoma. Am. J. Pathol. 155 (1999) 441-452
6. Pike S.E., Yao L., Jones K.D., Cherney B., Appella E., Sakaguchi K., et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med. 188 (1998) 2349-2356
7. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130 (1995) 503-506
8. Zabrenetzky V., Harris C.C., Steeg P.S., and Roberts D.D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59 (1994) 191-195
9. Campbell S.C., Volpert O.V., Ivanovich M., and Bouck N.P. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 58 (1998) 1298-1304
10. Zaloudek C.J., and Hendrickson C.J. Mesenchymal tumors of the uterus. In: Kurman R.J. (Ed). Blaustein's pathology of the female genital tract (2002), Springer Verlag, New York 561-615
11. Vollenhoven B.J., Lawrence A.S., and Healy D.L. Uterine fibroids: a clinical review. Br. J. Obstet. Gynecol. 97 (1990) 285-298
12. Mittal K., and Demopoulos RI. MIB-1 (Ki67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Human Pathol. 32 9 (2001) 984-987
13. Bell S.W., Kempson R.L., and Hendirckson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am. J. Surg. Pathol. 18 6 (1994) 535-538
14. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Ass. 53 (1958) 457-481
15. Bodner-Adler B., Bodner K., Czerwenka K., Kimberger O., Leodolter S., and Mayerhofer K. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol. Oncol. 96 1 (2005) 62-66
16. Mayerhofer K., Lozanov P., Bodner K., Bodner-Adler B., Obermair A., Kimberger O., et al. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecol. Oncol. 92 1 (2004) 175-179
17. Zhang Y.W., Su Y., Volpert O.V., and Vande Woude G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl. Acad. Sci. U. S. A. 100 22 (2003) 12718-12723
18. Sid B., Sartelet H., Bellon G., El Btaouri H., Rath G., Delorme N., et al. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit. Rev. Hematol. 49 3 (2004) 245-258
19. Detmar M. Tumor angiogenesis. J. Investig. Dermatol. Symp. Proc. 5 1 (2000) 20-23
20. Wu M.P., Tzeng C.C., Wu L.W., Huang K.F., and Chou C.Y. Thrombospondin 1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. J. Cancer 10 1 (2004) 27-32
21. Campbell S.C., Volpert O.V., Ivanovich M., and Bouck N.P. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 58 (1998) 1298-1304
22. Maeda K., Nishiguchi Y., Kang S.-M., Yashiro M., Onoda N., Sawada T., et al. Expression of thrombospondin-1 inversely correlated with tumor vascularity and haematogenous metastasis in colon cancer. Oncol. Rep. 8 (2001) 763-766
23. Sutton C.D., O'Byrne K., Goddard J.C., Marshall L.J., Jones L., Garcea G., et al. Expression of Thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin. Cancer Res. 11 (2005) 6567-6573
24. Salvesen H.B., and Akslen L.A. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer 84 (1999) 539-543